Rituximab
Brand and Other Names:
Rituxan
Mechanism of Action:
Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes.
Indications:
RITUXAN is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
Route:
Intravenous
Dose:
Standard Infusion: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr. (See Full Prescribing Information.)
Adverse Reactions:
Infusion-related reactions, Severe mucocutaneous reactions, Hepatitis B reactivation with fulminant hepatitis, Progressive multifocal leukoencephalopathy, Tumor lysis syndrome, Cardiovascular adverse reactions, Infections, Bowel obstruction. (See Full Prescribing Information.)
Contraindication:
None
Warnings and Precautions:
RITUXAN can cause severe, including fatal, infusion-related reactions. Severe reactions typically occurred during the first infusion with time to onset of 30–120 minutes.
See package insert for full prescribing information.